(1 - 13 von 15
)
Novartis : data highlight benefit of early treatment initiation in ...www.marketscreener.com › news
www.marketscreener.com
... helps slow disability progression and declining cognitive function,' said Norman Putzki, M.D., Global Head of Development Neuroscience.
Novartis highlights cognition data in secondary progressive multiple...
www.myscience.ch
· Norman Putzki, Global Program Head, Neuroscience at Novartis, said: "Mayzent is the only US Food and Drug Administration approved therapy ...
Novartis announces new Mayzent® (siponimod) data show
www.globenewswire.com
· ... its long-term effect on delaying progression and cognitive impairment,” said Norman Putzki, MD, Global Head of Development Neuroscience.
Students take on the challenges of digital medicine | Novartis
www.novartis.com
“It's an exercise in creative problem-solving,” said Norman Putzki, M.D., Global Program Head, Neuroscience at Novartis and creator of this ...
sortiert nach Relevanz / Datum